OBX (Obsidian Therapeutics) Common Stock: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OBX Obsidian Therapeutics Inc OBX
11 GF Score
Price $17.27
! 1 Warning Sign
View Full Analysis

What is Obsidian Therapeutics Common Stock?

Obsidian Therapeutics OBX -0.35% 11 Common Stock is $0.00 Mil as of Jun. 2026. GuruFocus rates OBX with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Obsidian Therapeutics's quarterly common stock increased from Dec. 2025 ($0.08 Mil) to Mar. 2026 ($4.37 Mil) but then declined from Mar. 2026 ($4.37 Mil) to Jun. 2026 ($0.00 Mil).

Obsidian Therapeutics's annual common stock increased from Dec. 2023 ($0.05 Mil) to Dec. 2024 ($4.45 Mil) but then declined from Dec. 2024 ($4.45 Mil) to Dec. 2025 ($0.08 Mil).

Obsidian Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Obsidian Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Obsidian Therapeutics Common Stock Chart

Obsidian Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only 0.03 0.03 0.05 4.45 0.08

Obsidian Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.67 2.65 0.08 4.37 0.00
OBX
11GF Score
Obsidian Therapeutics Inc OBX
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Obsidian Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.00 Mil mean?
Obsidian Therapeutics (OBX) has a Common Stock of $0.00 Mil as of Jun. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Obsidian Therapeutics and its competitors.
Is Obsidian Therapeutics' Common Stock too high?
Obsidian Therapeutics' current Common Stock is $0.00 Mil. Overall, Obsidian Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Obsidian Therapeutics' Common Stock compare to LXRX and SLNCF?
Obsidian Therapeutics' Common Stock of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Obsidian Therapeutics and its competitors. Obsidian Therapeutics's current Common Stock is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Obsidian Therapeutics stock overvalued right now?
Obsidian Therapeutics (OBX) has a current Common Stock of $0.00 Mil. The current Common Stock is $0.00 Mil. Obsidian Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Obsidian Therapeutics (OBX), the current Common Stock is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Obsidian Therapeutics Business Description

Address 1030 Massachusetts Avenue, Suite 400, Cambridge, MA, USA, 02138
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States that develops engineered cell therapies for solid tumors. The company's proprietary cytoDRiVE platform uses drug-responsive domains to regulate protein function, and its lead programs apply this technology to engineered tumor-infiltrating lymphocyte (TIL) therapies, known as cytoTILs. Its main product candidate, OBX-115, is an autologous, genetically engineered TIL therapy designed to eliminate the need for systemic interleukin-2 administration, and it is being evaluated in clinical trials for melanoma and non-small cell lung cancer. Obsidian also pursues additional engineered cell therapy programs built on its platform. The company operates as a research and development-stage business, funding its activities primarily through equity financing, partnerships, and collaboration arrangements rather than product revenue, and it targets oncology markets in the United States and other regions.
11GF Score

Get the complete analysis for OBX

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.27
Price